Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Deborah Collyar: What's In It for Patients?

Opportunities to Optimize Cancer Policies Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




May
19
Today In Oncology
Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer
Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age
FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2 Positive Early Breast Cancer
Adding Capivasertib to Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: The Patient Experience
Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo